Skip to main content
Canna~Fangled Abstracts

Acidic Cannabinoids Suppress Proinflammatory Cytokine Release by Blocking Store-operated Calcium Entry

By July 8, 2022December 10th, 2024No Comments


doi: 10.1093/function/zqac033. eCollection 2022.

Affiliations 

Abstract

Cannabis sativa has long been known to affect numerous biological activities. Although plant extracts, purified cannabinoids, or synthetic cannabinoid analogs have shown therapeutic potential in pain, inflammation, seizure disorders, appetite stimulation, muscle spasticity, and treatment of nausea/vomiting, the underlying mechanisms of action remain ill-defined. In this study we provide the first comprehensive overview of the effects of whole-plant Cannabis extracts and various pure cannabinoids on store-operated calcium (Ca2+) entry (SOCE) in several different immune cell lines. Store-operated Ca2+ entry is one of the most significant Ca2+ influx mechanisms in immune cells, and it is critical for the activation of T lymphocytes, leading to the release of proinflammatory cytokines and mediating inflammation and T cell proliferation, key mechanisms for maintaining chronic pain. While the two major cannabinoids cannabidiol and trans-Δ9-tetrahydrocannabinol were largely ineffective in inhibiting SOCE, we report for the first time that several minor cannabinoids, mainly the carboxylic acid derivatives and particularly cannabigerolic acid, demonstrated high potency against SOCE by blocking calcium release-activated calcium currents. Moreover, we show that this inhibition of SOCE resulted in a decrease of nuclear factor of activated T-cells activation and Interleukin 2 production in human T lymphocytes. Taken together, these results indicate that cannabinoid-mediated inhibition of a proinflammatory target such as SOCE may at least partially explain the anti-inflammatory and analgesic effects of Cannabis.

Keywords: Interleukin-2, calcium inhibitor, calcium-release activated calcium, cannabigerolic acid, cannabinoids, inflammation

Figures

Graphical Abstract

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

References

    1. Urits I, Borchart M, Hasegawa Met al. . An update of current Cannabis-based pharmaceuticals in pain medicine. Pain Ther. 2019;8(1):41–51. – PMC – PubMed
    1. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manage. 2008;4(1):245–259. – PMC – PubMed
    1. Russo EB, Marcu J. Chapter Three—Cannabis pharmacology: the usual suspects and a few promising leads. In: Kendall D, Alexander SPH, eds. Cannabinoid Pharmacology. Vol 80. San Diego, CA: Academic Press, 2017:67–134. – PubMed
    1. Lewis MA, Russo EB, Smith KM.. Pharmacological foundations of Cannabis chemovars. Planta Med. 2018;84(4):225–233. – PubMed
    1. Cassano T, Villani R, Pace Let al. . From Cannabis sativa to cannabidiol: promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11(11):124. – PMC – PubMed

Leave a Reply